Rhythm Pharmaceuticals has reported sustained reductions in body mass index (BMI) after two years of treatment with setmelanotide in patients with acquired hypothalamic obesity, with results from its Phase 3 TRANSCEND trial presented at ObesityWeek 2026.
Patients who received setmelanotide continuously recorded an average BMI reduction of 18.8% after two years. Those who initially received placebo before switching to setmelanotide after 12 months achieved an average reduction of 16.5%.
The results were based on 81 patients who had completed two years of treatment in the trial’s long-term extension. A total of 125 patients entered the extension, with all participants receiving open-label setmelanotide after the first year.
Among adult patients, average BMI reductions reached 21.2% for those treated continuously and 21.0% for those who switched from placebo. Paediatric patients also recorded improvements, with BMI z-scores falling by an average of 1.71 and 1.49 respectively across the two treatment groups.
The safety profile was generally consistent with previous clinical trials of setmelanotide in acquired hypothalamic obesity.
Acquired hypothalamic obesity is a rare condition caused by damage or dysfunction affecting the hypothalamus, a region of the brain involved in regulating hunger and body weight. It can develop following brain tumours, surgery, traumatic brain injury or other forms of injury. Patients can experience excessive weight gain, persistent hunger and reduced energy expenditure.
Setmelanotide, marketed as IMCIVREE, works by activating the melanocortin-4 receptor pathway, which plays a role in regulating appetite and energy balance.
Rhythm Pharmaceuticals is held in the portfolio of The Biotech Growth Trust. The company’s shares represented approximately 2.39% of the trust’s portfolio as at 31 July 2026, according to the latest holdings information available. The investment gives the trust exposure to the development and commercialisation of treatments for rare obesity and other neuroendocrine conditions.
Biotech Growth Trust plc (LON:BIOG) seeks capital appreciation through investment in the worldwide biotechnology industry. The Company and the Company’s Portfolio Manager believe that there is a high congruence between companies that seek to act responsibly and those that succeed in building long-term shareholder value.








































